Shares of Advanced Cell Technology Inc. (OTC: ACTC), a biotechnology company engaged in the development and commercialization of human embryonic and adult stem cell technology in the fast growing field of regenerative medicine, are gaining in trading today.
At last check, ACTC shares were trading 4.71% higher at $0.0890 on volume of 4.62 million. The stock gained 6.1% in the last three trading sessions.
Last week, Advanced Cell Technology announced treatment of the fourth patient, the first in the second patient group, in the U.S. clinical trial for Stargardt’s Macular Dystrophy (SMD). The surgery, performed at Wills Eye Institute in Philadelphia, was done by a surgical team led by Carl D. Regillo, MD, FACS, Director of the Wills Eye Clinical Retina Research Unit.
Gary Rabin, Chairman and CEO of Advanced Cell Technology, said last week that it is very gratifying to have second cohort, higher-dosage patient treatment underway in ACTC’s U.S. clinical trial for SMD.
Recent Comments